[1]苗 毅a,杨淑梅a,王 晶b,等.肺腺癌组织中MCM4 的表达及其与预后、免疫微环境的相关性分析[J].现代检验医学杂志,2023,38(05):115-120.[doi:10.3969/j.issn.1671-7414.2023.05.022]
　MIAO Yia,YANG Shumeia,WANG Jingb,et al.Expression of MCM4 in Lung Adenocarcinoma and Its Correlation with Prognosis and Immune Microenvironment[J].Journal of Modern Laboratory Medicine,2023,38(05):115-120.[doi:10.3969/j.issn.1671-7414.2023.05.022]
点击复制

肺腺癌组织中MCM4 的表达及其与预后、免疫微环境的相关性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年05期
页码:
115-120
栏目:
论著
出版日期:
2023-09-15

文章信息/Info

Title:
Expression of MCM4 in Lung Adenocarcinoma and Its Correlation with Prognosis and Immune Microenvironment
文章编号:
1671-7414（2023）05-115-06
作者:
苗 毅a; 杨淑梅a; 王 晶b; 武润苗a; 孙皎琳a; 吴军芳a
（陕西省人民医院 a. 呼吸与危重症医学科；b. 检验科，西安 710068）
Author(s):
MIAO Yia;  YANG Shumeia;  WANG Jingb;  WU Runmiaoa;  SUN Jiaolina;  WU Junfanga
（a. Department of Respiratory and Critical Care Medicine; b. Department of Clinical Laboratory, Shaanxi Provincial People’s Hospital, Xi’an 710068, China）
关键词:
肺腺癌; 微小染色体维持蛋白4; 肿瘤免疫微环境
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.05.022
文献标志码:
A
摘要:
目的 探讨肺腺癌（lung adenocarcinoma，LUAD）组织中微小染色体维持蛋白4（minichromosome maintenanceproteins 4， MCM4）的表达及其与预后、免疫微环境的相关性。方法 选取2021 年1 ～ 7 月陕西省人民医院收治的LUAD 患者4 例，应用转录组测序检测LUAD 患者癌组织和癌旁组织MCM4 表达水平。癌症基因组图谱肺腺癌(the cancer genome atla- LUAD，TCGA-LUAD) 数据用于验证LUAD 中 MCM4 表达并探究其与生存期的相关性。采用LinkedOmics 分析LUAD 中MCM4 共表达基因、功能富集及调控因子靶向富集情况。STRING 用于构建蛋白质- 蛋白质互作网络。采用TIMER 分析MCM4 与LUAD 肿瘤免疫微环境的相关性。COX 回归分析LUAD 患者预后的影响因素。结果 与癌旁组织比较，LUAD 癌组织中MCM4 表达水平（6.50±0.86 vs 4.22±0.66）升高，差异有统计学意义（U=16，P=0.029）。TCGA-LUAD 发现相似结果( 癌组织3.63±0.92 vs 癌旁组织1.90±0.28)， 差异有统计学意义（U =30 355，P < 0.001）。生存分析显示，MCM4 高表达LUAD 患者总生存期和无病生存期200 个月的累积生存率（8.79%和19.25%）均低于MCM4 低表达患者（28.87% 和36.82%），差异有统计学意义（风险比=1.7，1.4，均P<0.05）。共表达分析显示，LUAD 中与MCM4 正相关的基因主要参与P53 信号通路、DNA 复制、错配修复等通路。肿瘤免疫微环境分析显示，MCM4与中性粒细胞浸润呈正相关（partial.cor=0.14，P=0.002），与B细胞浸润呈负相关（partial.cor =-0.152，P<0.001）。COX 回归分析显示，MCM4 是影响LUAD 患者预后的独立因子。结论 LUAD 癌组织中MCM4 表达升高，与预后及免疫微环境显著相关，可作为LUAD 患者不良预后评估的分子标志物。
Abstract:
Objective To explore the expression of minichromosome maintenance proteins 4 (MCM4) in lung adenocarcinoma (LUAD) and its correlation with prognosis and immune microenvironment. Methods From January to July 2021, four LUAD patients admitted to Shaanxi Provincial People’s Hospital were selected and transcriptome sequencing was used to detect the expression level of MCM4 in LUAD cancer tissue and paracancerous tissue. TCGA-LUAD data was performed to validate the expression of MCM4 and explore its relevance to survival periods in LUAD. Co-expressed genes of MCM4, functional enrichment, and regulator target enrichment in LUAD were analyzed using LinkedOmics. STRING tool was adopted to construct the protein-protein interaction network. TIMER tool was utilized to investigate the relationship between MCM4 and the tumor immune microenvironment in LUAD. COX regression was used to analyze the influencing factors of prognosis for LUAD patients. Results Compared with the paracancerous tissues, the expression level of MCM4 in LUAD cancer tissues was increased (6.50±0.86 vs 4.22±0.66), and the difference was statistically significant (U=16, P=0.029). TCGA-LUAD data found a similar result (cancer tissues 3.63±0.92 vs paracancerous tissues 1.90±0.28), and the difference was statistically significant (U=30 355, P<0.001). Survival analysis showed that the 200-month cumulative survival rate of OS and DFS of LUAD patients with high-expression MCM4 (8.79% and 19.25%) was lower than that with low-expression MCM4 (28.87% and 36.82%), and the differences was statistically significant (HR=1.7, 1.4, all P<0.05). Co-expression analysis revealed that the genes that were positively correlated with MCM4 in LUAD, were mainly involved in the P53 signaling pathway, DNA replication, and mismatch repair. Tumor immune microenvironment analysis showed that MCM4 was positively correlated with the infiltration of Neutrophils (partial.cor=0.14, P=0.002), and negatively correlated with the infiltration of B cells (partial.cor= -0.152, P<0.001). COX regression analyses found that MCM4 was an independent factor affecting the prognosis of LUAD patients. Conclusion The expression of MCM4 was increased in LUAD cancer tissues, and it was obviously related to the prognosis and immune microenvironment, which can be applied as a molecular marker to evaluate the poor prognosis of LUAD patients.

参考文献/References:

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA-A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[2] DUMA N, SANTANA-DAVILA R, MOLINA J R. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment[J]. Mayo Clinic Proceedings, 2019, 94(8): 1623-1640.
[3] SWANTON C, GOVINDAN R. Clinical implications of genomic discoveries in lung cancer[J]. New England Journal of Medicine, 2016, 374(19): 1864-1873.
[4] CHAMPASA K, BLANK C, FRIEDMAN L J, et al. A conserved MCM4 motif is required for MCM2-7 double-hexamer formation and origin DNA unwinding[J]. Elife, 2019,8:e45538.
[5] ISHIMI Y. Regulation of MCM2-7 function[J]. Genes & Genetic Systems, 2018, 93(4): 125-133.
[6] CHENG Lin, TAN Zhangmin, HUANG Zenan, et al. Expression profile and prognostic values of Minichromosome maintenance families (MCMs) in breast cancer[J]. Medical Science Monitor, 2020, 26: e923673.
[7] ISSAC M S M, YOUSEF E, TAHIR M R, et al. MCM2, MCM4, and MCM6 in breast cancer: clinical utility in diagnosis and prognosis[J]. Neoplasia, 2019, 21(10): 1015-1035.
[8] KWOK H F, ZHANG Shudong, MCCRUDDEN C M, et al. Prognostic significance of minichromosome maintenance proteins in breast cancer[J]. American Journal of Cancer Research, 2015, 5(1): 52-71.
[9] XIE L, LI T, YANG L H. E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival[J]. European Review for Medical and Pharmacological Sciences, 2017, 21(9): 2150-2156.
[10] ZHOU Huandi, JIANG Le, WANG Guohui, et al. Identification of MCM4 as a prognostic marker of hepatocellular carcinoma[J]. BioMed Research International, 2021, 2021: 7479326.
[11] 刘宾, 刘辉, 李宝玉. 微小染色体维持蛋白4 在胰腺导管腺癌中的表达及其与预后相关性研究[J]. 国际生物医学工程杂志, 2021, 44(1): 28-33. LIU Bin, LIU Hui, LI Baoyu. Expression of minichromosome maintenance protein 4 in pancreatic ductal adenocarcinoma and its correlation with prognosis[J].International Journal of Biomedical Engineering, 2021, 44(1): 28-33.
[12] HUANG Chen, LEI Chuqi, PAN Boyu, et al. Potential prospective biomarkers for non-small cell lung cancer: mini-chromosome maintenance proteins[J]. Frontiers in Genetics, 2021, 12: 587017.
[13] LIU Kang, KANG Min, LIAO Xiwen, et al. Genome-wide investigation of the clinical significance and prospective molecular mechanism of minichromosome maintenance protein family genes in patients with lung Adenocarcinoma[J]. PLoS One, 2019, 14(7): e0219467.
[14] LI Shu, JIANG Zhou, LI Yirun, et al. Prognostic significance of minichromosome maintenance mRNA expression in human lung adenocarcinoma[J]. Oncology Reports, 2019, 42(6): 2279-2292.
[15] 赖凯, 宋从宽, 高明朗, 等. 肺腺癌关键基因及潜在药物的生物信息学分析[J]. 中华实验外科杂志,2022, 39(6): 1176-1179. LAI Kai, SONG Congkuan, GAO Minglang, et al. Bioinformatics analysis of hub genes and potential drugs in lung adenocarcinoma[J]. Chinese Journal of Experimental Surgery, 2022, 39(6): 1176-1179.
[16] QIU Jiannan, ZHANG Shaopeng, WANG Peng, et al. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway[J].Cancer Medicine, 2020, 9(21): 8159-8172.
[17] FU Xin, CHEN Guo, CAI Zhiduan, et al. Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer[J]. OncoTargets and Therapy, 2016, 9: 2211-2220.
[18] CHEN Honglin, LEE J, KLJAVIN N M, et al. Requirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinoma[J]. Genes & Cancer, 2015, 6(3/4): 106-118.
[19] CHEN Jie, LIAO Yi, FAN Xianming. Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis[J].Expert Review of Anticancer Therapy, 2021, 21(7): 795-803.
[20] DRACEA A, ANGELESCU C, DANCIULESCU M, et al. Mismatch repair gene expression in gastroesophageal cancers[J]. the Turkish Journal of Gastroenterology, 2015, 26(5): 373-377.
[21] QI Lina, ZHOU Biting, CHEN Jiani, et al. Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer[J]. Journal of Cancer, 2019, 10(26): 6618-6634.
[22] LUO Xiping, HONG Xiaoshan, XIONG Xingdong, et al. A single nucleotide polymorphism in EXO1 gene is associated with cervical cancer susceptibility in Chinese patients[J]. International Journal of Gynecological Cancer, 2012, 22(2): 220-225.
[23] ZHOU Changshuai, FENG Mingtao, CHEN Xin, et al. Exonuclease 1 (EXO1) is a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma[J]. Onco Targets Ther, 2021,14: 1033-1048.
[24] YANG Xiaosong, PAN You, QIU Zhaojun, et al. RNF126 as a biomarker of a poor prognosis in invasive breast cancer and CHEK1 inhibitor efficacy in breast cancer cells[J]. Clinical Cancer Research, 2018, 24(7): 1629-1643.
[25] JIANG Jiahong, WANG Shaohai, WANG Zehua, et al. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer[J]. Cancer Chemotherapy and Pharmacology, 2020, 86(2): 295-305.
[26] KENT L N, LEONE G. The broken cycle: E2F dysfunction in cancer[J]. Nature Reviews Cancer, 2019, 19(6): 326-338.
[27] LIANG Yuxiang, LU Jianming, MO Rujun, et al. E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer[J]. International Journal of Oncology, 2016, 48(4): 1650-1658.
[28] 张涛元, 丁雪梅, 李俏, 等. 人非小细胞肺癌组织中转录因子E2F 家族表达与临床病理特征及预后的相关性分析[J]. 现代检验医学杂志, 2022, 37(4): 87-91. ZHANG Taoyuan, DING Xuemei, LI Qiao, et al. Correlation analysis of transcription factor E2F family expression with clinicopathological features and prognosis in human non-small cell lung cancer [J]. Journal of Modern Laboratory Medicine, 2022, 37(4): 87-91.
[29] GORGOULIS V G, ZACHARATOS P, MARIATOS G, et al. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas[J]. Journal of Pathology, 2002, 198(2): 142-156.
[30] FELICIANO A, GARCIA-MAYEA Y, JUBIERRE L, et al. MiR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer[J].Cell Death Dis, 2017, 8(10): e3141.
[31] 汪倩玲, 张逸寅, 王华, 等. 中性粒细胞在肿瘤微环境、肿瘤发生发展及诊治中的作用[J]. 生理科学进展, 2022, 53(1): 1-6. WANG Qianling, ZHANG Yiyin, WANG Hua, et al. Role of neutrophils in microenvironment progression, diagnosis and treatment of tumors [J]. Progress in Physiological Sciences, 2022, 53(1): 1-6.

相似文献/References:

[1]刘　欣,张欢欢,关　平,等.肺腺癌细胞中长链非编码 RNA- ARAP1-AS1 表达模式及其生物学特征[J].现代检验医学杂志,2021,36(03):38.[doi:10.3969/j.issn.1671-7414.2021.03.009]
　LIU Xin,ZHANG Huan-huan,GUAN Ping,et al.Expression Pattern and Biological Characteristics of ARAP1-AS1 in LungAdenocarcinoma Cells[J].Journal of Modern Laboratory Medicine,2021,36(05):38.[doi:10.3969/j.issn.1671-7414.2021.03.009]
[2]王利民,刘　锴.TUBA1C促进人肺腺癌细胞系增殖和迁移的机制研究[J].现代检验医学杂志,2021,36(04):74.[doi:10.3969/j.issn.1671-7414.2021.04.016]
　WANG Li-min,LIU Kai.Study on the Mechanism of TUBA1C Promoting Proliferation and Migrationof Lung Adenocarcinoma Cells[J].Journal of Modern Laboratory Medicine,2021,36(05):74.[doi:10.3969/j.issn.1671-7414.2021.04.016]
[3]胡艳正,牛彦杰,石鹏飞.长链非编码RNA LINC00222对肺腺癌细胞增殖、迁移、侵袭和凋亡的影响及作用机制的研究[J].现代检验医学杂志,2021,36(05):16.[doi:10.3969/j.issn.1671-7414.2021.05.004]
　HU Yan-zheng,NIU Yan-jie,SHI Peng-fei.Effect of Long Non Coding RNA LINC00222 on Proliferation, Migration,Invasion and Apoptosis of Lung Adenocarcinoma Cells and Its Mechanism[J].Journal of Modern Laboratory Medicine,2021,36(05):16.[doi:10.3969/j.issn.1671-7414.2021.05.004]
[4]鲍培龙,徐月亮,王孝彬.miR-153对肺腺癌细胞增殖、侵袭、迁移和凋亡的影响及机制研究[J].现代检验医学杂志,2022,37(01):107.[doi:10.3969/j.issn.1671-7414.2022.01.022]
　BAO Pei-long,XU Yue-liang,WANG Xiao-bin.Effects of miR-153 on Proliferation, Invasion, Metastasis and Apoptosis of Lung Adenocarcinoma Cells and Its Mechanism[J].Journal of Modern Laboratory Medicine,2022,37(05):107.[doi:10.3969/j.issn.1671-7414.2022.01.022]
[5]董胜鉴,黄丽丽,李树锦.肺腺癌患者血清中miR-498，miR-339-5p和miR-210-3p水平表达的临床诊断价值[J].现代检验医学杂志,2022,37(02):58.[doi:10.3969/j.issn.1671-7414.2022.02.012]
　DONG Sheng- jian,HUANG Li- li,LI Shu -jin.Clinical Diagnostic Value Expressed at miR-498, miR-339-5p and miR-210-3p Levels in Serum in Patients with Lung Adenocarcinoma[J].Journal of Modern Laboratory Medicine,2022,37(05):58.[doi:10.3969/j.issn.1671-7414.2022.02.012]

备注/Memo

备注/Memo:
基因项目：陕西省重点研发计划项目(NO.2020DLSF01-06)：OPN/FOXM1信号通路在慢性阻塞性肺疾病气道重塑中的机制研究及临床价值。
作者简介：苗毅(1984-)，女，硕士，副主任医师，研究方向：慢性气道疾病及肺部肿瘤研究, E-mail：Stella hx@163.com。
通讯作者：吴军芳(1983-)，女，硕士，主治医师，研究方向：肺恶性疾病发病机制,E-mail：lddaltt060215@163.com。
更新日期/Last Update: 2023-09-15